Polypeptide Group AG

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
H6306W109
SEDOL
BP5GVW6
CIK
N/A
polypeptide.com
LEI:
©
FIGI: BBG0100P02P0
PPGN
Polypeptide Group AG
GICS: 35203010 · Sector: - · Sub-Sector: -
AI
PROFILER
NAME
Polypeptide Group AG
ISIN
CH1110760852
TICKER
PPGN
MIC
XSWX
REUTERS
PPGN.S
BLOOMBERG
PPGN SW
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Mon, 16.12.2024

PolyPeptide Group / Key word(s): Miscellaneous Large-scale SPPS capacity in Braine-l’Alleud starts production 16.12.2024 / 07:00 CET/CEST Media release Large-scale SPPS capacity in Braine-l’Alleud starts production Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based activ...
Research & Analysis
Read more
Tue, 13.08.2024

Media release – ad hoc announcement pursuant to Art. 53 LR                Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028 Baar, 13 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, today announced its results f...
Research & Analysis
Read more
Thu, 08.08.2024

PolyPeptide Group / Key word(s): Personnel PolyPeptide appoints Chief Commercial Officer 08.08.2024 / 20:00 CET/CEST Media release PolyPeptide appoints Chief Commercial Officer Baar, 8 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ing...
Research & Analysis
Read more
Wed, 10.04.2024

PolyPeptide Group / Key word(s): AGMEGM PolyPeptide announces results of the annual General Meeting 2024 10.04.2024 / 19:23 CET/CEST Media release PolyPeptide announces results of the annual General Meeting 2024 Baar, 10 April 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleot...
Research & Analysis
Read more
Tue, 19.03.2024

PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2024 19.03.2024 / 07:00 CET/CEST Media release PolyPeptide publishes invitation to the annual General Meeting 2024 Baar, 19 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligon...
Research & Analysis
Read more
Tue, 12.03.2024

Media release – ad hoc announcement pursuant to Art. 53 LR   PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow Baar, 12 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical in...
Research & Analysis
Read more
Tue, 31.10.2023

PolyPeptide Group / Key word(s): Partnership/ESG PolyPeptide signs scientific collaboration agreement 31.10.2023 / 07:00 CET/CEST Media Release                             PolyPeptide signs scientific collaboration agreement Strasbourg, 31 October 2023 – PolyPeptide today announced the signing of a collaboration agre...
Research & Analysis
Read more
Mon, 02.10.2023

PolyPeptide Group / Key word(s): Financing PolyPeptide secures revolving credit facility 02.10.2023 / 07:00 CET/CEST Media Release PolyPeptide secures revolving credit facility Baar, 2 October 2023 – PolyPeptide Group AG (SIX: PPGN) announces the signing of a revolving credit facility agreement with Credit S...
Research & Analysis
Read more
Tue, 15.08.2023

Media release – ad hoc announcement pursuant to Art. 53 LR                Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO Baar, 15 August 2023 – PolyPeptide today announced its results for H1 2023, updated guidance for 2023 and the appointment of its new CFO: Reported re...
Research & Analysis
Read more
Thu, 13.07.2023

Media Release – ad hoc announcement pursuant to Art. 53 LR  PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023 Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide business. It expects 2023 to be ...
Research & Analysis
Read more
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S